Testing and measurement 361 items
Whom to test and when, mg/dL versus nmol/L, isoform-insensitive assays and the LC-MS/MS reference method, thresholds (30, 50, 70, 90 mg/dL; 75, 125, 150, 175, 200 nmol/L), the low testing rates and the once-in-a-lifetime recommendation.
Trials, agents, guidance
- Guideline NLA focused update on the use of Lp(a) in clinical practice (2024)
- Guideline EAS consensus statement on Lp(a) in ASCVD and aortic stenosis (2022)
Studies
- OCEAN(a)-DOSE: olpasiran lowers Lp(a) by more than 95 percent in patients with ASCVD (O'Donoghue et al., NEJM 2022)
- The 2022 EAS consensus statement on Lp(a) in ASCVD and aortic stenosis (Kronenberg, Mora, Stroes et al., EHJ 2022)
- Pelacarsen (AKCEA-APO(a)-LRx) lowers Lp(a) by up to 80 percent in patients with cardiovascular disease: the phase 2 trial (Tsimikas et al., NEJM 2020)
- Genetically elevated Lp(a) causes myocardial infarction: the Copenhagen Mendelian randomisation (Kamstrup et al., JAMA 2009)
- Lp(a)FRONTIERS APHERESIS: pelacarsen replaces lipoprotein apheresis in 25 of 26 patients (Parhofer et al., EHJ 2026)
- Design and rationale of Lp(a)HORIZON, the first Lp(a) outcomes trial: pelacarsen in 8,323 patients (Cho, Nicholls, Nordestgaard et al., Am Heart J 2025)
- ALPACA: lepodisiran 400 mg lowers Lp(a) by 94 percent from day 60 to 180, and by 95 percent over a year with a second dose (Nissen et al., NEJM 2025)
- KRAKEN: oral muvalaplin lowers Lp(a) by 82 to 86 percent on an intact-particle assay (Nicholls et al., JAMA 2025)
- Baseline and on-statin Lp(a) predict events in statin trials: patient-level meta-analysis (Willeit et al., Lancet 2018)
- How much Lp(a) lowering equals 1 mmol/L of LDL-C? The Mendelian randomisation answer (Burgess et al., JAMA Cardiol 2018)
- IONIS-APO(a)Rx and the GalNAc-conjugated APO(a)-LRx: two dose-ranging trials (Viney et al., Lancet 2016)
- Elevated Lp(a) and risk of aortic valve stenosis in the general population (Kamstrup et al., JACC 2014)
- Lp(a) as a cardiovascular risk factor: the first EAS consensus panel (Nordestgaard et al., EHJ 2010)
- 2026 ACC/AHA multisociety guideline on the management of dyslipidemia (Blumenthal, Morris et al., Circulation 2026)
- 2025 focused update of the 2019 ESC/EAS dyslipidaemia guidelines (Mach, Koskinas, Roeters van Lennep et al., EHJ 2025)
- Lp(a) risk persists at the lowest achieved LDL-C: participant-level meta-analysis of six statin trials (Bhatia et al., Circulation 2025)
- ALPACAR: zerlasiran lowers time-averaged Lp(a) by more than 80 percent over 36 weeks in ASCVD (Nissen et al., JAMA 2024)
- Inflammation, cholesterol, Lp(a) and 30-year cardiovascular outcomes in women (Ridker et al., NEJM 2024)
- Lp(a) is about six times more atherogenic than LDL per particle: apoB-based Mendelian randomisation (Björnson et al., JACC 2024)
- Lepodisiran phase 1: a single 608 mg dose keeps Lp(a) 94 percent down at day 337 (Nissen et al., JAMA 2023)
- Muvalaplin, the first oral inhibitor of Lp(a) formation: phase 1 (Nicholls et al., JAMA 2023)
- Alirocumab-induced Lp(a) lowering independently predicts fewer MACE after ACS: ODYSSEY OUTCOMES (Bittner et al., JACC 2020)
- 2019 ESC/EAS guidelines for the management of dyslipidaemias (Mach et al., EHJ 2020)
- Lp(a) molar concentration, not apo(a) size, drives cardiovascular risk; loss of Lp(a) raises diabetes risk: deCODE (Gudbjartsson et al., JACC 2019)
- How much Lp(a) lowering for a clinically relevant CHD reduction? The Lp(a)-GWAS-Consortium estimate (Lamina and Kronenberg, JAMA Cardiol 2019)
- Lp(a) and oxidised phospholipids drive valve calcification activity and progression in aortic stenosis (Zheng et al., JACC 2019)
- Lp(a) and myocardial infarction across seven ethnic groups: INTERHEART (Paré et al., Circulation 2019)
- Lp(a), PCSK9 inhibition and cardiovascular risk in FOURIER (O'Donoghue et al., Circulation 2019)
- Lp(a) measurements for clinical application: why the assays disagree (Marcovina and Albers, J Lipid Res 2016)
- First antisense drug against apo(a) in humans: ISIS-APO(a)Rx phase 1 (Tsimikas et al., Lancet 2015)
- First-degree relatives of people with elevated Lp(a) have more MACE: Swedish registry cohort (Kindborg et al., EHJ 2026)
- Lp(a) predicts coronary events but not stroke, and evolocumab benefits at any Lp(a): VESALIUS-CV (Monguillon et al., Circulation 2026)
- Safety of low Lp(a): no excess of bleeding, malignancy, neurocognitive events or AF, but more diabetes: FOURIER (Gencer et al., EHJ 2026)
- Thirty-year cardiovascular risk in healthy women by Lp(a) threshold: the Women's Health Study (Nordestgaard AT et al., JAMA Cardiol 2026)
- Lp(a) and recurrent ASCVD in 273,770 US patients: risk rises continuously to a hazard ratio of 1.45 above 300 nmol/L (MacDougall et al., EHJ 2025)
- What existing lipid-lowering drugs do to Lp(a): meta-analysis of 147 RCTs (Xie et al., Atherosclerosis 2025)
- Only 13 percent of coronary patients worldwide would meet a 150 nmol/L trial threshold: INTERASPIRE (Barkas et al., JACC 2025)
- NLA focused update 2024: measure Lp(a) at least once in every adult, with three risk bands (Koschinsky et al., J Clin Lipidol 2024)
- Lp(a) drives ASCVD, MI and aortic stenosis risk independent of C-reactive protein: Copenhagen (Thomas et al., EHJ 2023)
- Lp(a) levels in a global ASCVD population: Lp(a)HERITAGE (Nissen et al., Open Heart 2022)
- APOLLO: single ascending doses of SLN360 (zerlasiran) lower Lp(a) by up to 98 percent (Nissen et al., JAMA 2022)
- AHA scientific statement: Lp(a) is a genetically determined, causal and prevalent risk factor for ASCVD (Reyes-Soffer et al., ATVB 2022)
- An LC-MS/MS candidate reference method for standardising Lp(a) measurement (Marcovina et al., Clin Chem 2021)
- Lp(a) lowering by alirocumab reduces total cardiovascular events independent of LDL-C: ODYSSEY OUTCOMES (Szarek et al., EHJ 2020)
- Statin therapy increases Lp(a) levels: subject-level meta-analysis of six trials (Tsimikas et al., EHJ 2020)
- Arterial wall inflammation persists in high-Lp(a) patients despite 60 percent LDL-C lowering with evolocumab (Stiekema et al., EHJ 2019)
- High Lp(a) and high risk of cardiovascular and all-cause mortality (Langsted et al., EHJ 2019)
- Elevated Lp(a) and risk of ischaemic stroke, observational and genetic (Langsted et al., JACC 2019)
- NLA scientific statement: use of Lp(a) in clinical practice, a biomarker whose time has come (Wilson et al., J Clin Lipidol 2019)
- A test in context: Lp(a) diagnosis, prognosis, controversies and emerging therapies (Tsimikas, JACC 2017)
- Five years of lipoprotein apheresis for Lp(a)-associated disease: the German prospective follow-up (Roeseler et al., ATVB 2016)
- High Lp(a) as a possible cause of clinical familial hypercholesterolaemia (Langsted et al., Lancet Diabetes Endocrinol 2016)
- Low Lp(a) and large apo(a) isoforms are causally linked to type 2 diabetes (Kamstrup and Nordestgaard, Lancet Diabetes Endocrinol 2013)
- IL-6 modifies Lp(a)-associated coronary risk but not aortic stenosis risk: UK Biobank (JAMA Cardiol 2026)
- Obicetrapib lowers Lp(a) by 37 percent (15 nmol/L) in high-risk patients: pooled analysis (Nicholls et al., EHJ 2026)
- mg/dL to nmol/L: the Copenhagen formula beats the factor 2.5 in the Lp(a)HORIZON screening population (Atherosclerosis 2026)
- Cascade screening for Lp(a) from coronary patients: three relatives to screen per case found (Littmann et al., Atherosclerosis 2026)
- Regular aspirin use and lower incidence of aortic valve calcium and severe stenosis in people with high Lp(a): MESA (Razavi et al., EHJ 2026)
- Oxidised phospholipids on apoB predict MACE after ACS and alirocumab abolishes the relation: ODYSSEY OUTCOMES (Tsimikas et al., Circulation 2025)
- Twelve years of lipoprotein apheresis for Lp(a)-associated progressive ASCVD: Pro(a)LiFe (Klingel et al., Atherosclerosis 2025)
- One-time LDL-C, hs-CRP and Lp(a) screening predicts 20-year events in European men and women: EPIC-Norfolk (Kraaijenhof, Nurmohamed et al., EHJ 2025)
- The Brussels International Declaration on Lp(a) testing and management (Kronenberg et al., Atherosclerosis 2025)
- Olpasiran lowers oxidised phospholipids on apoB by about 90 percent without moving hs-CRP or IL-6: OCEAN(a)-DOSE (Rosenson et al., JAMA Cardiol 2025)
- After stopping olpasiran, Lp(a) stays 40 to 50 percent below baseline for nearly a year: OCEAN(a)-DOSE extension (O'Donoghue et al., JACC 2024)
- Zerlasiran single and multiple doses in ASCVD patients: Lp(a) down 90 percent at 201 days after two doses (Nissen et al., JAMA 2024)
- Lp(a) testing in a large US academic health system: 0.3 percent of adults over ten years (Bhatia et al., JAHA 2023)
- Thirty frequent questions on the 2022 EAS Lp(a) consensus, answered (Kronenberg, Mora, Stroes et al., Atherosclerosis 2023)
- Lp(a) in children with suspected familial hypercholesterolaemia (de Boer et al., EHJ 2023)
- Lp(a) is associated with the onset but not the progression of aortic valve calcification: the Rotterdam Study (Kaiser et al., EHJ 2022)
- Ancestry, Lp(a) and cardiovascular risk thresholds (Tsimikas and Marcovina, JACC 2022)
- Sex differences in Lp(a) levels and associated risk by age: Copenhagen (Simony et al., Atherosclerosis 2022)
- Finding very high Lp(a): the case for routine assessment (Nurmohamed et al., Eur J Prev Cardiol 2022)
- Lp(a) measurement issues: a mountain out of a molehill? (Kronenberg, Atherosclerosis 2022)
- Pelacarsen lowers Lp(a) cholesterol and reveals how much of 'LDL-C' is really Lp(a) (Yeang et al., JACC 2022)
- 2021 Canadian Cardiovascular Society dyslipidaemia guidelines: Lp(a) once in a lifetime (Pearson et al., Can J Cardiol 2021)
- Genetically elevated Lp(a) shortens parental lifespan and health span (Arsenault et al., JAMA Netw Open 2020)
- HEART UK consensus statement on Lp(a): a call to action (Cegla et al., Atherosclerosis 2019)
- Whole-genome sequencing of Lp(a) in European and African ancestries (Zekavat et al., Nat Commun 2018)
- NHLBI working group recommendations to reduce Lp(a)-mediated risk of CVD and aortic stenosis (Tsimikas et al., JACC 2018)
- LPA variants, apo(a) isoforms and events differ by ethnicity: the Dallas Heart Study (Lee et al., Circulation 2017)
- Lp(a): the impact of ethnicity and of environmental and medical conditions (Enkhmaa et al., J Lipid Res 2016)
- Elevated Lp(a) and LPA risk genotypes raise the risk of heart failure (Kamstrup and Nordestgaard, JACC Heart Fail 2016)
- Olpasiran and apolipoprotein B particles: what siRNA-mediated Lp(a) removal does to the apoB pool (Zimerman et al., JAMA Cardiol 2025)
- Lp(a) and dementia in 539,478 people: no association with Alzheimer's or vascular dementia on continuous scales (Thomas et al., EHJ 2025)
- Lp(a) as a pharmacological target: premises, promises and prospects (Greco et al., Circulation 2025)
- Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial
- The French Society of Atherosclerosis issues a consensus statement recommending Lp(a) testing be covered by national health insurance (Arch Cardiovasc Dis 2021)
- Formula-based Lp(a)-C estimates overstate cholesterol content and understate true LDL-C, direct-assay study of 278 patients (J Clin Lipidol 2026)
- Machine learning finds 26-253% more elevated-Lp(a) cases per test than universal screening, model of 438,579 (Eur J Prev Cardiol 2026)
- Taiwan Society of Lipid and Atherosclerosis issues 2026 Lp(a) consensus on diagnosis and risk management (J Formos Med Assoc 2026)
- Lp(a) testing is linked to more aggressive lipid treatment and better LDL-C goal attainment, Veterans Affairs cohort of 6.9 million (J Am Heart Assoc 2026)
- Canadian Cardiovascular Society practical framework for Lp(a) screening, risk assessment and management (Can J Cardiol 2026)
- STAR-Lp(a) study finds meaningful Lp(a) drift within 1-3 years in 1,263 patients, challenging the once-in-a-lifetime testing recommendation (Med Sci (Basel) 2025)
- Korean Lp(a) task force proposes a 3-tier classification (30/50 mg/dL) tailored to Korean cohorts, position paper (J Lipid Atheroscler 2026)
- Only 1 in 20 young ischemic stroke patients had ever been tested for Lp(a) by 2024, despite testing more than doubling since 2015, 188,305-patient US analysis finds (J Stroke Cerebrovasc Dis 2026)
- Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis
- Lp(a) stays stable at the extremes but a third of mid-range patients reclassify to higher risk, 230,018-adult Korean study finds (Atherosclerosis 2025)
- Only 1.4% of ASCVD-free and 4.9% of ASCVD patients were ever tested for Lp(a) over 18 years, but testing tracked with more lipid-lowering therapy use, 419,812-patient Midwest cohort finds (Am J Prev Cardiol 2025)
- Lp(a) testing for primary prevention is cost-saving across every high-income country modelled, multinational microsimulation finds (Atherosclerosis 2025)
- A new genomic method predicting Lp(a) from exome data flags high-risk individuals better than prior tools, especially outside European ancestry, 76,147-person study finds (JACC Basic Transl Sci 2025)
- Kronenberg group finds Lp(a) is truly stable once technical variability is removed, suggesting reported fluctuations are largely assay noise (Atherosclerosis 2025)
- Just 0.8% of a diverse 266,612-person US cohort had ever been tested for Lp(a), with Black participants 32% less likely to be tested, All of Us study finds (JACC Adv 2025)
- In 44,354 Korean adults, having both high Lp(a) and coronary calcium raises ASCVD odds 2.4-fold, more than either marker alone (J Clin Lipidol 2025)
- Amsterdam UMC's decade-long serial CT scans show high Lp(a) drives more plaque, more low-density plaque and more pericoronary inflammation (JAMA Cardiol 2024)
- MESA study of 6,792 participants over 16.7 years finds a zero aortic valve calcium score beats Lp(a) or LDL-C for ruling out future severe aortic stenosis (Circ Cardiovasc Imaging 2024)
- ARISE machine-learning tool, validated across four cohorts totalling nearly 480,000 people, cuts the number needed to test for elevated Lp(a) by up to 67.3% (Nat Cardiovasc Res 2024)
- Mass, molar and mass-spectrometry Lp(a) assays predict cardiovascular risk and alirocumab benefit equally in 11,970 ODYSSEY OUTCOMES patients (Circulation 2024)
- Median Lp(a) ranges from 12 to 41 nmol/L across Hispanic/Latino backgrounds in the US, tracking genetic ancestry, in 16,117 HCHS/SOL participants (JAMA Cardiol 2023)
- Standard LDL-C tests only predict cardiovascular risk because they secretly include Lp(a) cholesterol, reclassifying up to 41% of patients once corrected, an analysis spanning 531,144 lab patients (J Am Heart Assoc 2020)
- Testing for Lp(a) during FH cascade screening finds new high-Lp(a) relatives and quadruples cardiovascular risk when both are present, SAFEHEART study of 2,927 relatives (J Am Coll Cardiol 2019)
- The standard 30 mg/dL Lp(a) cutoff misses risk in white and Hispanic adults, who need the 50 mg/dL threshold instead, the MESA study across 4 races (Arterioscler Thromb Vasc Biol 2015)
- Lp(a) improves 15-year cardiovascular risk prediction, especially for people at intermediate risk, the Bruneck Study of 826 adults (J Am Coll Cardiol 2014)
- Lp(a) barely changes after eating or with inflammation, and still predicts heart disease regardless, a Danish study of 34 829 people (Atherosclerosis 2014)
- Adding Lp(a) nearly doubles lipid-lowering-treatment eligibility in a 24,994-person primary-prevention cohort, SCAPIS (Atherosclerosis 2026)
- Lp(a) fluctuates substantially in youth with type 1 diabetes, challenging the single-lifetime-measurement paradigm, 286-patient cohort (Cardiovasc Diabetol 2026)
- High Lp(a) causes concentration-dependent overestimation of standard LDL-C assays, 1,560-sample methodology study (J Lipid Res 2026)
- Lipoprotein(a) and residual cardiovascular risks in Japanese patients with coronary artery disease who achieve guideline-recommended LDL-C goals
- Comparative associations of LDL-C, Lp(a), hsCRP, and IL-6 with cardiovascular risk: Insights from the UK Biobank and MESA
- Lp(a) above 58 mg/dL overestimates LDL-C by 10% or more across all major formulas, study of 3,923 (Clin Lab 2026)
- Lp(a) uniquely predicts low-density noncalcified plaque beyond CAC and hsCRP, CCTA cohort of 547 (Eur Heart J Cardiovasc Imaging 2026)
- Cholesterol content per Lp(a) particle rises with larger apo(a) isoform size, direct-assay study of 94 (J Lipid Res 2026)
- Lipoprotein(a), High-Sensitivity C-Reactive Protein, and Incident ASCVD Risk in Individuals Without Standard Modifiable Risk Factors
- Sex Differences in Lipids and Lipoproteins and Their Relationship With Cardiovascular Disease: A Prospective Study of UK Biobank Participants
- Menopause transition triggers a fourfold larger Lp(a) rise than staying pre- or postmenopausal, UK Biobank preprint of 4,562 women (medRxiv 2026)
- Cascade screening for elevated Lp(a) in relatives of children who visited the pediatric lipid clinic: yield of daily clinical practice
- Lp(a) variability after ACS mainly reclassifies intermediate-risk patients, cohort of 235 (J Clin Med 2026)
- Linear and Nonlinear Associations Between Lipoprotein(a) and the Risks of Atherosclerotic Cardiovascular Disease
- Global Lp(a) standardization nears reality with a mass-spectrometry reference method, review (Clin Chem Lab Med 2026)
- New assay reveals Lp(a) particles are 4-fold richer in triglycerides in hypertriglyceridemia, method study of 150 (J Lipid Res 2026)
- Time-weighted Lp(a) outpredicts single-measurement Lp(a) for calcific aortic valve disease, cohort of 5,156 (Lipids Health Dis 2026)
- The Lp(a) implementation gap: screening stays below 1% despite affecting 20% of the world, review (Rev Cardiovasc Med 2026)
- Lp(a) varies little within individuals, repeat testing rarely needed, cohort of 250 (J Clin Lipidol 2026)
- Lp(a) above 50 mg/dL predicts MACE and improves SCORE2/PCE performance, ambulatory cohort of 3,052 (Clin Res Cardiol 2026)
- Lp(a) concentrations vary more than 100-fold by ancestry, yet the relative ASCVD risk per unit is universal, review of ancestral variation finds (Curr Atheroscler Rep 2025)
- Fifteen years of Lp(a) guidelines have moved toward universal screening, but important evidence gaps remain, Boffa, Koschinsky and Hegele find (Curr Opin Lipidol 2025)
- Only half of physicians with access to Lp(a) testing use it routinely, and a third can't define an elevated result, INTERASPIRE survey across 7 countries finds (Eur J Prev Cardiol 2025)
- 1 in 5 patients show high Lp(a) variability between tests, with the biggest risk-category churn in the 'gray zone,' Korean multicenter study of 5,305 finds (Lipids Health Dis 2025)
- Patients with prior ASCVD and Lp(a) above 90 mg/dL rack up 2.5 times higher healthcare costs and more MACE than those with normal Lp(a), Alberta real-world study of 29,229 finds (Atherosclerosis 2025)
- Lp(a) stays stable at the extremes, but women, statin users and those with ASCVD or high LDL-C are more likely to see borderline levels shift, 11,669-patient Mayo Clinic study finds (Eur J Prev Cardiol 2025)
- Global Lp(a) testing rose from 0.009% to just 0.032% of adults between 2015 and 2023, TriNetX analysis of 141 million patients finds (Am Heart J 2025)
- Lp(a) meets most established criteria for a population screening test, on health, societal and cost grounds, review by Koschinsky and Thanassoulis's group argues (Eur J Prev Cardiol 2025)
- Only 0.5% of 150,083 Mexican tertiary-care patients were tested for Lp(a), and just 26% of those with elevated levels got risk-modifying treatment (Lipids Health Dis 2025)
- Mass-based and molar-based Lp(a) immunoassays are interchangeable, near-identically predicting coronary and aortic valve calcification, Rotterdam Study of 5,129 finds (Am Heart J 2025)
- NIRS imaging in the REASSURE registry shows combined LDL-C and Lp(a) control cuts high-risk lipid-core plaque by about 70% (J Clin Lipidol 2025)
- CDC standardization program finds Lp(a) interassay variability up to 69.1% across eight clinical laboratories (J Clin Lipidol 2025)
- A new isoform-insensitive Lp(a) particle assay reveals commercial assays underestimated muvalaplin's efficacy (J Lipid Res 2025)
- Across 5 US health systems, just 0.4% of 595,684 ASCVD patients were tested for Lp(a), with older and Black patients tested least (J Am Heart Assoc 2024)
- A new nanopore sequencing method resolves the notoriously complex LPA KIV-2 repeat region with near-ddPCR accuracy across five ancestries (Genome Med 2024)
- Just 0.42% of 700,580 Japanese ASCVD-prevention patients were tested for Lp(a), despite 7% of those tested exceeding the risk threshold, claims database study finds (J Atheroscler Thromb 2025)
- A repeat Lp(a) test reclassifies over half of patients out of the EAS 'grey zone', in a study of 609 individuals (Eur Heart J Open 2024)
- Switching Lp(a) assays at a Norwegian national lab changed who counted as high-risk: the Roche assay flagged 80% more patients above 180 mg/dL than Siemens (Am J Prev Cardiol 2024)
- ApoB and Lp(a) testing make up less than 1% of all US lipid panel testing, across four national claims databases (Am J Prev Cardiol 2024)
- Review by Koschinsky, Rosenson and colleagues explains why Lp(a) runs up to threefold higher across racial groups and 5-10% higher in women (J Am Heart Assoc 2024)
- Black and Hispanic ASCVD patients had Lp(a) tested at roughly a tenth the rate of White patients, despite higher median levels, in 56,833 records (medRxiv 2024)
- Among 13,689 tested Californians, Black patients had 2.5-fold higher odds of Lp(a) above 50 mg/dL than the overall population (JACC Adv 2024)
- Nordestgaard-led study of 15 Danish lipid clinics finds elevated Lp(a) explains 27% of clinical familial hypercholesterolaemia diagnoses (J Clin Endocrinol Metab 2024)
- A faster LC-MS comparison method matches the Lp(a) reference measurement procedure, easing the shift to molar reporting units (Clin Proteomics 2024)
- Non-Hispanic Black and Hispanic patients are tested for Lp(a) far less often than white patients despite higher levels, in 56,833 US medical records (J Clin Lipidol 2024)
- Elevated Lp(a) is already present by age 5 and remains largely unmodifiable by lifestyle or lipid drugs, a review by a leading Lp(a) assay expert (Crit Rev Clin Lab Sci 2023)
- 75.5% of surveyed European lipid clinicians routinely measure Lp(a), but reimbursement and treatment gaps remain barriers, an EAS Lipid Clinics Network survey (Atherosclerosis 2023)
- Lp(a) testing is performed in only 0.34% of German patients, but when done, is linked to better cardiovascular outcomes, an analysis of 4 million claims records (Atherosclerosis 2023)
- Only 0.25% of 2.4 million patients in a US healthcare network have ever had Lp(a) measured, with striking demographic testing gaps (J Clin Lipidol 2023)
- Correcting LDL-C for genetically estimated Lp(a) reclassifies up to 9% of suspected FH patients as unlikely FH, in 1,504 Dutch referrals (Atherosclerosis 2023)
- Pelacarsen and olpasiran achieve up to 90% Lp(a) reductions, positioning routine Lp(a) testing as clinically essential, a review (Curr Opin Lipidol 2023)
- Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy
- Lp(a) rises 22-43% from childhood to adulthood depending on lipid-lowering treatment, with 70% intra-individual variation, in 2,740 Dutch children (Atherosclerosis 2022)
- Lp(a) above the 90th percentile nearly doubles aortic valve stenosis incidence over 14 years, in 23,298 routinely tested Swedes (Atherosclerosis 2022)
- A single Lp(a) measurement suffices for CAD risk prediction, since repeat levels stay 96% correlated over years, in 16,017 UK Biobank participants (J Am Coll Cardiol 2022)
- Lp(a) above the 90th decile raises coronary artery disease risk by 62% in routinely tested patients, a 14-year Swedish follow-up of 23,398 people (Eur J Prev Cardiol 2022)
- Lp(a) makes up 15% of all atherogenic particles at the highest Lp(a) levels, a particle-based analysis of 158,260 patients (J Clin Lipidol 2022)
- Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
- A new assay measuring Lp(a)-carried cholesterol shows standard LDL-C tests overestimate true LDL by up to 17 mg/dL, in patients with high Lp(a) (J Lipid Res 2021)
- Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial
- Six commercial Lp(a) immunoassays diverge from a reference standard by -8% to +22%, a comparison of 144 samples (Atherosclerosis 2019)
- Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial
- Different Lp(a) assay methods perform similarly for predicting valve and coronary disease, but only in white participants, a MESA study of 4679 adults (Clin Chem 2017)
- The standard 30 mg/dL Lp(a) cutoff predicts aortic valve calcification in white and Black adults, but not Hispanics or Chinese, the MESA study of 4678 adults (Arterioscler Thromb Vasc Biol 2016)
- Coronary disease risk rises at Lp(a) levels below the standard 50 mg/dL threshold, an EPIC-Norfolk study of 623 cases and 948 controls across two assays (J Lipid Res 2016)
- A common lab method for estimating Lp(a) cholesterol correlates poorly with actual Lp(a) mass, risking misclassified risk, a study of 552 patients (J Clin Lipidol 2016)
- Adjusting the Friedewald LDL formula for Lp(a) does not improve heart disease risk prediction, the Quebec Cardiovascular Study of 2222 men (Atherosclerosis 2002)
- Falling triglycerides shift Lp(a) density in step with LDL, independent of apo(a) size, a study of 75 people (Arterioscler Thromb Vasc Biol 2001)
- A new antibody detects oxidized Lp(a) specifically, revealing higher levels in hypertensive patients with complications, a Japanese study (Circulation 2000)
- A newer Lp(a)-cholesterol assay adds no predictive value over standard Lp(a) mass testing, a WOSCOPS nested case-control study of 238 controls and 108 cases (Atherosclerosis 2000)
- Lp(a) drives premature cardiovascular disease even at goal LDL-C, review calls for universal testing and cascade screening (Eur J Prev Cardiol 2026)
- Coronary imaging reveals how Lp(a) drives plaque burden and high-risk morphology, review (Curr Atheroscler Rep 2026)
- Lp(a) testing is available but underused in Argentina, national survey of 518 laboratories and 18,159 test results (J Clin Lipidol 2026)
- Elevated Lp(a) is linked to 3.5-times higher odds of treatment intensification, 530-patient academic health-center study (J Clin Lipidol 2026)
- Lp(a) of 149 nmol/L or more flags greater anatomic coronary disease burden, angiography registry of 2230 (Cardiovasc Revasc Med 2026)
- 1 in 5 children with suspected FH have Lp(a) 105 nmol/L or more, Japanese pediatric screening cohort of 97 (J Atheroscler Thromb 2026)
- Clinical risk factors cannot distinguish FH from elevated Lp(a), 378-patient lipid clinic study argues for universal genetic and Lp(a) testing (J Clin Lipidol 2026)
- First nmol/L-standardised Lp(a) distribution in Japanese patients proposes 25 and 125 nmol/L risk thresholds, LEAP study (J Atheroscler Thromb 2026)
- Queensland Lp(a) testing rose from 652 to 4,364 tests a year over a decade, still underused (Heart Lung Circ 2026)
- Patients find Lp(a) testing acceptable and motivating despite no approved therapy, INTERASPIRE survey across seven countries (Eur J Cardiovasc Nurs 2026)
- About 1 in 10 Finnish adults has elevated Lp(a), nationally representative survey of 5,484 (Lipids Health Dis 2026)
- Adding Lp(a) improves pre-test probability calibration for obstructive CAD, derivation cohort of 4,262 (Eur Heart J Cardiovasc Imaging 2026)
- Women have higher Lp(a) than men in acute coronary syndrome, Portuguese cohort of 388 (Rev Port Cardiol 2026)
- Association of Coronary Microvascular Dysfunction with Lipoprotein (a) levels in Patients with Non-Obstructive Coronary Artery Disease
- Lipoprotein(a) levels in children with hypercholesterolemia
- Machine learning cuts number needed to test by more than 50% for finding elevated Lp(a), review of the ARISE framework (Curr Opin Lipidol 2026)
- LDL-C targets are met in only a fifth of very-high-Lp(a) patients despite statins, Spanish lipid-unit study of 265 (Clin Investig Arterioscler 2026)
- New point-of-care device shows strong correlation with lab Lp(a) assays, validation study of 58 samples (Clin Chem Lab Med 2026)
- Routine Lp(a) testing changed management in most UK lipid clinic patients above 50 mg/dL, even without an Lp(a)-specific drug (Curr Med Res Opin 2026)
- Lp(a) shows no significant link to MASLD, meta-analysis of 21 studies and 418,755 (Front Nutr 2026)
- Fixed 30% Lp(a)-cholesterol correction can misclassify risk, review calls for harmonised molar reporting (Int J Gen Med 2026)
- Two isotope-dilution mass spectrometry reference materials for Lp(a), certified at 212.50 and 40.82 nmol/L, aim to standardise clinical assays (Int J Biol Macromol 2026)
- Lp(a) testing rose from 3,052 to 8,425 orders a year across a US health system, cohort of 450,412 (Am J Prev Cardiol 2026)
- Only 36.7% of surveyed Latin American physicians request Lp(a) testing, citing unavailability and cost as the main barriers (BMC Cardiovasc Disord 2025)
- 81% of US clinicians see Lp(a) as a major risk driver, but only 41% back universal testing, national survey of 2,002 (Am J Prev Cardiol 2026)
- A Cleveland Clinic Journal of Medicine primer distills what clinicians need to know about Lp(a) risk, screening and emerging therapies (Cleve Clin J Med 2025)
- Nearly a quarter of a Dubai multiethnic cohort has high-risk Lp(a), independent of LDL-C, study of 746 (Int J Cardiol 2026)
- A clinical practice review of Lp(a) risk stratification and the emerging lowering agents (Eur J Clin Invest 2026)
- Cutting dietary saturated fat raises Lp(a) levels and reshapes its lipid composition, not just its concentration, two DELTA feeding trials find (Nutrients 2025)
- Lp(a) has reached a 'tipping point' where universal one-time screening is justified today, Bhatia argues (Am J Prev Cardiol 2025)
- Nearly 30% of Irish lipid-clinic patients have Lp(a) above 125 nmol/L, largest Irish distribution study finds, with levels higher in women (Ir J Med Sci 2025)
- Lp(a) testing is already actionable in primary prevention, Parcha and Bittner argue, proposing a pragmatic clinical framework (Am Heart J Plus 2025)
- One in five people worldwide has elevated Lp(a), yet testing rates remain poor, review of emerging knowledge and therapies finds (Curr Cardiol Rep 2025)
- Why, how, and in whom to measure Lp(a): a review makes the case for prioritising African and South Asian ancestry patients alongside familial and premature ASCVD groups (Diabetes Obes Metab 2025)
- Cutting saturated fat raises Lp(a) even as it lowers LDL-C, a diet effect long assumed not to exist, updated review argues (Nutrients 2025)
- One in four clinicians never checks Lp(a), narrative review finds, blaming cost, isoform variability and thin treatment options for its clinical neglect (J Cardiovasc Dev Dis 2025)
- A clinical review by Thanassoulis's group consolidates Lp(a) biology, phenotypes and the late-phase therapeutic pipeline for practising clinicians (Clin Biochem 2025)
- A UK reference-change-value study finds Lp(a) must shift by more than 24-32% between tests to represent a real biological change (Ann Clin Biochem 2025)
- Lp(a) affects up to a quarter of the world's population and carries FH-comparable risk, review argues for universal adult screening and selective pediatric testing (Am J Prev Cardiol 2025)
- Review argues coronary artery calcium and Lp(a) testing should be used together, not as alternatives, in intermediate-risk prevention (Curr Cardiol Rep 2025)
- A machine-learning tool (ARISE) could raise Lp(a) testing yield in health systems where only 0.4% of patients are tested (Circ Genom Precis Med 2025)
- The Batary survey of 49 Spanish laboratories finds most lack Lp(a) testing protocols despite 46.87% of results exceeding 30 mg/dL (Clin Investig Arterioscler 2025)
- Fewer than one in four patients with elevated Lp(a) had their lipid-lowering therapy intensified within 30 days (J Clin Lipidol 2025)
- Survey of 1,001 people with elevated Lp(a) finds most share results with family, but decision regret shapes whether they test their children (J Clin Lipidol 2025)
- The largest Arabian Gulf survey of its kind finds only 23.6% of 1,069 physicians have ever ordered an Lp(a) test (J Clin Lipidol 2025)
- Recalibrating five Lp(a) immunoassays against an IFCC mass-spectrometry reference sharply cuts inter-method variability, Japanese harmonization study finds (J Atheroscler Thromb 2025)
- Only 1.0% of a 1.48 million-person Northern California cohort ever received Lp(a) testing, with sharp racial disparities (J Gen Intern Med 2025)
- A new short-read caller for the KIV-2 repeat region correlates with Lp(a) protein levels and reveals distinct ancestry-specific copy-number distributions (BMC Med Genomics 2024)
- Only 3% of 150,000 Chinese health-checkup attendees were tested for Lp(a), yet it still predicted carotid plaque and thickening, cross-sectional study finds (J Atheroscler Thromb 2025)
- At Mayo Clinic, only 0.15% of 257,225 patients with a lipid panel had Lp(a) tested within a year, and results rarely changed treatment (Am J Prev Cardiol 2024)
- A machine-learning decision tree using LDL-C, CHD status, family history and age identifies clusters with up to 91.1% prevalence of elevated Lp(a) (Int J Cardiol 2025)
- Lp(a) testing among US veterans rose ninefold from 2014 to 2023, but remains extremely rare and unevenly distributed (Am J Prev Cardiol 2024)
- Amsterdam UMC case-based review argues interventional cardiologists should measure Lp(a) routinely, given liberal but under-used guideline endorsement (Expert Rev Cardiovasc Ther 2024)
- One in three stable lipid-clinic patients showed Lp(a) swings over 25%, challenging the once-in-a-lifetime testing dogma (Med Clin (Barc) 2024)
- Johns Hopkins testing rate for Lp(a) rose tenfold over five years, but only 20% of those found elevated got a new prescription (Am J Prev Cardiol 2024)
- A new Lp(a)-inclusive risk calculator recategorised two-thirds of 671 patients upward, but an average 21 mg/dL LDL-C cut could offset most of the added risk (High Blood Press Cardiovasc Prev 2024)
- Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl
- Lp(a) is rarely tested before cardiac rehab despite high prevalence, German registry of 3,393 (Clin Res Cardiol 2026)
- Only 81% of surveyed UK lipid clinics can measure Lp(a), and reporting units still vary widely, a national survey (J Clin Lipidol 2024)
- Lp(a) testing rose 109% over five years at a UAE quaternary centre, and abnormal Lp(a) tracked with cardiovascular disease in 5,677 tested patients (Front Cardiovasc Med 2024)
- Low pretreatment Lp(a) predicts EGFR mutations and shorter progression-free survival in 338 lung adenocarcinoma patients on EGFR-TKI therapy (Int J Gen Med 2024)
- Hegele, Mancini and colleagues update how to apply Lp(a) in ASCVD risk assessment under Canada's once-in-a-lifetime testing guideline (CJC Open 2024)
- Cascade testing for Lp(a) yields 4x more elevated cases when starting from FH index patients who also have high Lp(a), in 103 children and adolescents (J Clin Lipidol 2024)
- UK national survey finds only 3 of 65 responding labs had fully adopted the 2019 HEART UK Lp(a) standardisation recommendations (Ann Clin Biochem 2024)
- Lipoprotein(a) should be measured once in a lifetime as part of standard non-fasting lipid testing, German national guidance argues (Dtsch Arztebl Int 2023)
- Lp(a) reaches adult levels by age 2 and stays stable for life, supporting a single universal screening test in youth aged 9-11 or 17-21, a review (Curr Atheroscler Rep 2023)
- Lp(a) is higher in Black populations and in women, but a lack of standardised assays and cutoffs still limits clinical use, a review (Best Pract Res Clin Endocrinol Metab 2023)
- Lp(a) testing rose steadily but remained rare at the University of Rochester Medical Center, identifying only 2,698 patients ever tested (J Clin Lipidol 2023)
- A new formula corrects LDL cholesterol for lipoprotein(a) cholesterol content, eliminating negative values seen with the standard 30% assumption (Cardiovasc Drugs Ther 2024)
- Elevated Lp(a) (>50 mg/dL) doubles coronary event risk even in older men, a prospective study of 755 individuals followed 8 years (J Lipid Res 2022)
- A new isoform-independent Lp(a) ELISA matches the gold-standard assay and mass spectrometry with over 97% correlation (J Lipid Res 2022)
- Up to a quarter of familial hypercholesterolaemia diagnoses are actually driven by high Lp(a), not LDL cholesterol itself, a review argues for updating diagnostic criteria (Curr Atheroscler Rep 2022)
- About 20% of people have elevated Lp(a), yet guidelines diverge sharply on how to manage it, and youth recommendations barely exist, a review (Curr Opin Endocrinol Diabetes Obes 2021)
- Lp(a)-derived cholesterol inflates LDL-C readings in 30-50% of familial hypercholesterolaemia patients, complicating diagnosis, a review (Curr Opin Lipidol 2020)
- An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial
- The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
- Advanced liver fibrosis from NASH lowers Lp(a) levels, undermining its value as a cardiovascular risk marker in 176 patients (Atherosclerosis 2020)
- Lp(a) above 50 mg/dL raises cardiovascular risk, above 180 mg/dL matches familial hypercholesterolaemia, a review 57 years after Lp(a) discovery (Prog Cardiovasc Dis 2020)
- Lp(a) varies up to 1000-fold between individuals, and 1 in 4 has levels that raise cardiovascular risk, a review asking if Lp(a) is ready for clinical use (Cardiol Clin 2018)
- Lp(a) molar-to-mass conversion ratios vary two to three-fold by assay and isoform, a study of 1635 samples across 5 commercial tests (J Clin Lipidol 2018)
- Antisense therapy could push Lp(a) below the 30-50 mg/dL risk threshold, a review of Lp(a) mechanisms and emerging therapeutics (Crit Rev Clin Lab Sci 2018)
- Lp(a) varies by more than 25% at some point in 40% of placebo patients in antisense trials, a temporal variability study of 52 subjects (J Clin Lipidol 2018)
- Elevated Lp(a) is common in patients needing coronary intervention despite controlled risk factors, but screening does not change physician treatment decisions, a study of 113 patients (J Clin Lipidol 2017)
- Lp(a) is significantly higher in patients with abdominal aortic aneurysm, a meta-analysis of 9 studies (Angiology 2017)
- One Lp(a) test can reclassify up to 40% of intermediate-risk patients, a review of Lp(a) re-emergence in clinical practice (Prog Cardiovasc Dis 2016)
- India lacks its own Lp(a) threshold, using a 20 mg/dL cutoff versus 30 mg/dL for Caucasians, a review of Lp(a) as a unique risk factor for coronary disease (Indian J Clin Biochem 2016)
- Two common Lp(a) assays disagree on classification for 23% of patients, a study of 144 patients (J Clin Lipidol 2012)
- Lp(a) particle behavior shifts dramatically with high triglycerides, correlating mainly with HDL subfractions instead, a study of 148 patients (J Clin Lipidol 2012)
- Lp(a) does not predict early carotid thickening, suggesting a thrombotic rather than atherogenic mechanism, a Spanish study of 172 healthy adults (Eur J Prev Cardiol 2012)
- 84% of high-Lp(a) patients in a lipid clinic were not on niacin despite meeting treatment criteria, a cohort of 692 patients (J Clin Lipidol 2012)
- A new chromatography method for measuring Lp(a) cholesterol correlates strongly with standard assays, a methods study (J Lipid Res 2010)
- A rapid qPCR method replaces laborious electrophoresis for counting Lp(a) gene repeats, a methods study (J Lipid Res 2009)
- Lp(a) adds modest but real predictive value for MACE after acute coronary syndrome, 300-patient cohort (J Clin Med 2026)
- Distribution of Lipoprotein(a) concentrations in children and young people with Familial Hypercholesterolemia (FH) compared to those without FH: A systematic review and narrative synthesis
- Lp(a) and insulin resistance jointly predict atherosclerotic plaque with a U-shaped interaction, 10,753-person Chinese cohort (Lipids Health Dis 2026)
- From Phenotype to Genotype and Beyond: Insights into Familial Hypercholesterolemia and Familial Hypertriglyceridemia
- Improved diagnosis of familial hypercholesterolemia by correcting LDL-C for lipoprotein(a) in a German cohort
- Markedly elevated Lp(a) unmasks vulnerable plaque missed by a zero calcium score, case report in sarcoidosis (J Clin Lipidol 2026)
- Lp(a) screening moves toward routine clinical practice, review for advanced practice clinicians (JAAPA 2026)
- Serum and plasma Lp(a) measurements agree closely, ARIC study of 100 participants (J Clin Lipidol 2026)
- Monocyte-to-HDL and lymphocyte-to-monocyte ratios track with high Lp(a) in healthy adults, diagnostic accuracy study (Acta Cardiol Sin 2026)
- It's time to test all adults for Lp(a), commentary on the 2026 ACC/AHA guideline (J Clin Lipidol 2026)
- Prevalence of Lipoprotein(a) Testing in Patients With Atherosclerotic Cardiovascular Disease Within a Large Australian Cardiology Network
- Mass-spectrometry method changes the Lp(a) proteome, but a 34-protein core is method-independent (J Clin Med 2026)
- Association of Elevated Lipoprotein(a) and Diabetes Mellitus With Survival Outcomes in Patients With Coronary Artery Disease: Findings From the CIN-II and RED-CARPET Cohorts
- Lipoprotein(a) in familial hypercholesterolemia
- Quality-improvement initiative roughly doubles Lp(a) ordering in an outpatient cardiology clinic (J Clin Lipidol 2026)
- Serum Lp(a) predicts progression-free survival and severe adverse events in 227 lung adenocarcinoma patients on first-line chemoimmunotherapy (Front Immunol 2026)
- Only two of eighteen GPs routinely tested for Lp(a) before LILAC-for-Lp(a) training reshaped their confidence, multi-method study finds (Front Med (Lausanne) 2026)
- A minireview makes the case for standardised Lp(a) measurement as LDL-C-normal cardiovascular risk stays underexplained (Int J Mol Sci 2025)
- Cost, distress and clinician reluctance are the main barriers to Lp(a) testing, qualitative study of 50 participants (J Clin Lipidol 2026)
- 12% of Vietnamese cardiologists screened at a national congress had elevated Lp(a), even among those with well-controlled lipids, pilot study finds (Health Sci Rep 2025)
- Adding Lp(a) to SCORE2 reclassified most moderate-risk patients to high risk and made 61% eligible for statins, 140-subject study finds (Biomedicines 2025)
- Does Lp(a) protect against or promote cancer? Experimental and clinical evidence remain contradictory, review finds, with implications for anti-Lp(a) drugs (Semin Cancer Biol 2025)
- Combining the diagonal earlobe crease with Lp(a) gives a 0.729 AUC for diagnosing coronary heart disease, 862-patient study finds (Sci Rep 2025)
- A 44-year-old woman with low calculated ASCVD risk but severe, calcified coronary disease illustrates why Lp(a) testing shouldn't wait for guideline mandates, case-based review argues (Am Heart J Plus 2025)
- A 30-minute Lp(a) teaching session nearly tripled residents' Lp(a) test ordering and raised confidence scores from 10 to 24 out of 25 (Cureus 2025)
- An isoform-insensitive Lp(a) assay correlates well with traditional polyclonal methods in apheresis patients, pilot study argues for standardisation (J Clin Apher 2025)
- Real-world data on how elevated Lp(a) patients are actually managed remains scarce, review argues for national and international registries (Curr Opin Lipidol 2025)
- A new fully automated latex-immunoturbidimetric Lp(a) assay matches an existing commercial method with 0.9972 correlation, development study finds (Biotechnol Lett 2025)
- A clinician-focused review consolidates Lp(a)'s path from biomarker discovery to emerging targeted therapy (Am J Cardiol 2025)
- Lp(a) rose significantly 3 months after acute coronary syndrome in all 40 patients studied, challenging single-timepoint measurement (Pol Arch Intern Med 2025)
- 10-30% of the world's population has Lp(a) above 50 mg/dL, Spanish clinical laboratory review finds, mapping who to test and how (Adv Lab Med 2025)
- Patients call elevated Lp(a) an "invisible" disorder, with clinicians often reluctant to test given the lack of effective treatment (Patient Prefer Adherence 2025)
- 44% of Singapore cardiology and endocrinology specialists never test for Lp(a), mainly citing no effective treatment (Front Cardiovasc Med 2025)
- In a UK NHS lipid clinic, 46% of 192 tested patients had abnormal Lp(a), with 16% at high or very high HEART UK risk (Qatar Med J 2025)
- Qualitative interviews with 41 cardiology staff in Singapore reveal why Lp(a) testing still lags despite consensus guidance (PLoS One 2025)
- A one-off gamified lecture doubles resident Lp(a) knowledge scores and modestly lifts screening at an academic primary care clinic (J Clin Lipidol 2025)
- Clinically oriented review outlines how to bring Lp(a) testing into routine Polish practice under the 2025 ESC/EAS update (Arch Med Sci 2025)
- Pre-appointment EHR messages to providers more than triple Lp(a) test orders in a US community health system (Am J Prev Cardiol 2025)
- Only 212 Lp(a) tests were run per year across a nationwide Pakistani lab network, yet 37.2% of results exceeded 30 mg/dL (Glob Cardiol Sci Pract 2024)
- New LC-MS/MS method quantifies Lp(a) alongside 13 other apolipoproteins from just 5 microlitres of plasma (Analyst 2024)
- Review asks whether Lp(a) measurement is accurate enough yet to support large-scale outcome trials (Int J Cardiol 2024)
- Digital droplet PCR outperforms quantitative PCR for measuring the LPA KIV2 repeat that drives Lp(a) variability (J Clin Lab Anal 2024)
- Antisense and siRNA therapies have reopened the decades-long question of Lp(a)'s causal role, while US, Canadian and European testing guidance still diverges, review finds (Cardiol Rev 2025)
- Only 31% of University of Pennsylvania physicians regularly test for Lp(a), citing unfamiliarity and lack of outcomes data, a provider survey (J Clin Lipidol 2024)
- Combining Lp(a) with neck circumference improves diagnostic accuracy for coronary heart disease in 791 patients undergoing angiography (Int J Gen Med 2024)
- Review argues Lp(a) testing helps solve the ASCVD risk puzzle specifically for statin-poor-responders and diverse populations (Am Heart J Plus 2024)
- About 5% of the population has highly elevated Lp(a), a Norwegian review of assessment and treatment in clinical practice (Tidsskr Nor Laegeforen 2023)
- PCSK9 inhibitors are currently the most effective approved option for lowering Lp(a), but measurement itself lacks a reference standard, a review with practical recommendations (Heart 2022)
- Universal Lp(a) screening meets nearly every criterion except outcome-trial proof that lowering it helps, a review of detection strategies (Curr Opin Endocrinol Diabetes Obes 2023)
- From Kare Berg 1963 discovery to today targeted drugs, a practising clinician guide to Lp(a) (J Clin Med 2022)
- Genotyping for Lp(a)-raising variants adds little beyond simply measuring Lp(a) itself, a review of contemporary genetics and clinical use (Curr Opin Cardiol 2021)
- LDL-C measurements can misclassify familial hypercholesterolaemia when Lp(a)-cholesterol inflates the reading, a short laboratory-focused review (Cardiol Res 2020)
- Testing and emerging RNA-targeted therapies for Lp(a), a review of the case for population risk screening (Cardiol Rev 2020)
- Lp(a) is a proven causal cardiovascular risk factor but still lacks a specific therapy or standardised test, a review (J Clin Med 2019)
- Lp(a) apheresis may reduce limb events in peripheral arterial disease as effectively as it reduces coronary events, a review (Clin Res Cardiol Suppl 2019)
- Testing for elevated Lp(a) still lacks routine clinical adoption despite causal evidence, a review of screening barriers (Expert Rev Cardiovasc Ther 2019)
- Lp(a) re-emerges as a major cardiology focus more than 50 years after its discovery, a review for preventive cardiology (Prog Lipid Res 2017)
- Lp(a) remains an underused target in athero-thrombosis management due to assay standardization challenges, a review of Lp(a) mechanisms and therapy (J Cell Physiol 2018)
- Nephrological guidelines ignore Lp(a) despite its cardiovascular risk in chronic kidney disease, a review calling for better recognition (Clin Res Cardiol Suppl 2017)
- Lp(a) has modest predictive value for cardiovascular and cerebrovascular outcomes, a review of evidence-based questions still unanswered (Crit Rev Clin Lab Sci 2016)
- Only 4 studies have examined Lp(a) and arterial stiffness, but most find a positive link, a review of Lp(a) and vascular stiffness parameters (Pulse (Basel) 2015)
- Lp(a) mass measurements conflate particle size with true risk, a review calling for a mass-insensitive assay (J Clin Lipidol 2014)
- High Lp(a) drives premature, progressive coronary disease in a young woman despite optimal LDL-C control, case report (JACC Case Rep 2026)
- Analytical Validation of Direct Lipoprotein(a)-Cholesterol Assay
- A patient, his endocrinologist and a patient association describe living with, diagnosing and campaigning for elevated Lp(a) awareness (Cardiol Ther 2025)
- Perspective piece asks whether digital health tools can push Lp(a) testing toward the ubiquity of A1C (Front Cardiovasc Med 2025)
- In 67 statin-naive adults, Lp(a) is independent of the standard lipid profile but rises with age, reinforcing the case for dedicated screening (Wiad Lek 2025)
- Opinion review argues Lp(a) must move from a neglected biomarker to a routinely measured one now that lowering agents are near approval (Front Cardiovasc Med 2025)
- Case report: a veteran athlete with a QRISK3 score of 4.1% turns out to have 75% coronary stenosis driven by elevated Lp(a) (Front Cardiovasc Med 2025)
- Two women with normal cholesterol and low coronary calcium scores still had significant coronary disease and high Lp(a), a case report (J Clin Lipidol 2020)
- A liver transplant recipient developed elevated Lp(a) and accelerated atherosclerosis after transplantation, a case report (J Clin Lipidol 2016)
- Distribution of Lipoprotein(a) Levels and Clinical Associations in a Lebanese Adult Population: A Retrospective Observational Study
- Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target
- Diagnostic and Severity Assessment of Coronary Artery Disease Using ApoB/ApoA-I Ratio: Insights from a Statin-Treated Eastern European Cohort
- Lipoprotein(a) Concentration and Achieving Target Values of Low-Density Lipoprotein Cholesterol Calculated by Different Equations
- Clinical value of Lipoprotein(a) combined with CatLet coronary score in predicting adverse events after emergency PCI for AMI patients
- Association of lipoprotein(a), oxidized phospholipids and apolipoprotein B100 in acute ischemic stroke cohort
- Genetic Prediction of Circulating Lipoprotein(a) Levels in Diverse Populations
Video and podcasts
New Horizons in Dyslipidaemia 2026, session 3: lipoprotein(a) (Libby, Cho, Kronenberg, Mora)
AHA 2025: Lp(a) and ASCVD, translating causal evidence into practice (Michelle O'Donoghue)
ESC 2025: LipoaScreen, cascade screening for elevated Lp(a) in relatives (Jonas Brinck)
